Disease course in MS and the response to therapy vary from person to person, - facebook prikbord

The disease course in MS and the response to therapy vary from person to person, and there is currently no reliable means to tell early on how active any individual’s MS is likely to be. A scientific team has discovered that differences in active genes has the potential to be used to group people with MS into categories that predict disease course and response to therapy.

Read more about how this study takes a step towards personalized medicine for prognosis and treatment in MS.

RESEARCH UPDATES

Update: Canadian Government Announces Research Team Launching Clinical Trial to Treat CCSVI

Ginkgo Fails to Improve Cognitive Function in People with MS

Results published of successful phase III trials of oral BG-12 for relapsing MS

CLINICAL TRIALS

Investigators Recruiting for Study of Tysabri in Early Relapsing-Remitting MS

Investigators Recruiting for Study of Ofatumumab in RR MS

Recruiting for a Nationwide Study of an Investigational New Treatment for Spasticity

Scripps Clinic Recruiting People with Relapsing and Progressive MS

Visit our clinical trials page for more local opportunities.

To prevent mailbox filters from deleting mailings from National Multiple Sclerosis Society, Pacific South Coast Chapter, add karen.hooper@nmss.org to your address book.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis.
Learn about your options by talking to your health professional and contacting the National MS Society
at www.mspacific.org or 1-800-344-4867 (1-800-FIGHT-MS)

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://main.nationalmssociety.org/ or 1-800-FIGHT-MS (344-4867).

Our postal address is:
National Multiple Sclerosis Society
733 Third Avenue
New York, New York 10017